PPS LLBO (Thnx for update E-7-2)
Cyrcadia Breast Monitor System-
CBM
PPS Target—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
********************************************************
PubMed.gov
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device.
S VS, et al. Comput Methods Programs Biomed. 2020. PMID: 33007593
CONCLUSIONS: The results from the initial studies indicate that the CBM may be valuable for breast health monitoring un …Below,
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020.
Show details
Cite
Abstract:
Background: The most common breast cancer detection modalities are generally limited by radiation exposure, discomfort, high costs, inter-observer variabilities in image interpretation, and low sensitivity in detecting cancer in dense breast tissue. Therefore, there is a clear need for an affordable and effective adjunct modality that can address these limitations. The Cyrcadia Breast Monitor (CBM) is a non-invasive, non-compressive, and non-radiogenic wearable device developed as an adjunct to current modalities to assist in the detection of breast tissue abnormalities in any type of breast tissue.
Methods: The CBM records thermodynamic metabolic data from the breast skin surface over a period of time using two wearable biometric patches consisting of eight sensors each and a data recording device. The acquired multi-dimensional temperature time series data are analyzed to determine the presence of breast tissue abnormalities. The objective of this paper is to present the scientific background of CBM and also to describe the history around the design and development of the technology.
Results: The results of using the CBM device in the initial clinical studies are also presented. Twenty four-hour long breast skin temperature circadian rhythm data was collected from 93 benign and 108 malignant female study subjects in the initial clinical studies. The predictive model developed using these datasets could differentiate benign and malignant lesions with 78% accuracy, 83.6% sensitivity and 71.5% specificity. A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
Conclusions: The results from the initial studies indicate that the CBM may be valuable for breast health monitoring under physician supervision for confirmation of any abnormal changes, potentially prior to other methods, such as, biopsies. Studies are being conducted and planned to validate the technology and also to evaluate its ability as an adjunct breast health monitoring device for identifying abnormalities in difficult-to-diagnose dense breast tissue.
Keywords: Breast cancer; Circadian rhythm; Data mining; Machine learning; Predictive analytics; Thermal metabolomics; Wearable device.
Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors of this work declare that they have no conflicts of interest.
***********************************************************
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the Cyrcadia Breast Monitor -tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some Cyrcadia Breast Monitors...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Post# 27171
PHd cancer researcher perspective Hint: U may be induced to buy more shares!
Post# 27131 PPS it’s long,but conclusion: pps.22 or more (updated per above $.14 PPS)
Post#27094 Co marketing intent: the short “it’s happening”!
Post# 27061 Market size & Need: Summary-It’s Huge & Needed
Post# 26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$ (Insurance CO’s want this money saving technology)
Post #27037 Number of breast cancer cases & importance of early detection: “Your life may depend on it”.
Post#26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
Post#25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
iFlytec(Keda Xunfei) & Cyrcadia Health
Bloomberg Nov, 2017 iFlytec video (6 months after iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted saying...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley office”
Read between the lines, LLBO S/B trading above .05 cents per share.
Market Data 
Markets 
AI
